Skip to content
Accutar Biotech logo — Employ AI to Revolutionize Drug Discovery

Accutar Biotech

Employ AI to Revolutionize Drug Discovery

Founded 2015 United States Brooklyn, United States 38 employees Total: $72.75M AI, Biopharma +2

General Information

Company Name Accutar Biotech
Founded Year 2015
Location United States Brooklyn, United States
Employees 38
Industries AI, Biopharma, Biotechnology +1
Business Model B2B, SaaS, API
Revenue Model Licensing, Service Fee, Subscription
Social

BounceWatch is an independent company data service, not affiliated with Accutar Biotech. To contact Accutar Biotech, visit accutarbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Accutar Biotech compare?

A PDF of Accutar Biotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Accutar Biotech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Nov 02, 2026

Accutar Biotech achieved a preclinical milestone in its multi-target collaboration with Evommune for EVO646.

About Accutar Biotech

Accutar Biotech, founded in 2015, is disrupting the drug discovery industry by employing artificial intelligence to revamp traditional methodologies. Operating from Shanghai, China and New York, NY, the company leverages its AI-driven platforms to significantly cut down on the time and expenses associated with drug discovery.

Specializing in side chain flexible mode ligand docking, virtual screening, and ADME property prediction, Accutar’s solutions, like Chemi-Net and Orbital, outperform the current industry standards in their respective domains. The former is a molecular graph convolutional network improving drug property prediction accuracy, while the latter enhances docking precision in predicting protein-ligand complexes.

The company’s hybrid approach, combining computational design with wet lab validation, is gaining traction within biopharma and biotechnology sectors, evidenced by their $28.45M venture round investment on January 5, 2021. Accutar Biotech is strategically poised to forge strong academic and industry partnerships to solve cross-disciplinary challenges.

Business keywords: AI Drug Discovery, Computation-aided Drug Design, Flexible Mode Ligand Docking, Virtual Screening, ADME Prediction, Hybrid Drug Design Approach, Molecular Graph Convolutional Network, Deep Neural Network Docking, Lead Discovery Services, Lead Optimization, Intelligent-SAR, Biotech AI Solutions, Pharmaceutical Collaboration, Wet Lab Validation

Services & Products

AI Solutions for Drug Discovery
Drug Design and Development
AI-Powered Biological System Analysis
Data-Driven Chemical Analysis

Target Customers

Pharmaceutical Companies Biotech Firms Healthcare Researchers Cancer Treatment Specialists

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC Undisclosed 1
Coatue
01 Apr 2021
Round $28.45M -
01 Jan 2021
Early VC €15.30M 4
Karista, Newton BioCapital +2
01 Sep 2020
Early VC $28.00M -
01 Aug 2019
Series A Undisclosed -
01 Dec 2017
Seed CNY1.00M -
01 Jul 2015

Accutar Biotech Alternatives & Competitors

View All Alternatives
Accutar Biotech vs

Unifying AI and Biotech to accelerate the discovery of new medicines

157 employees
AI, Biotechnology
Accutar Biotech vs
Standigm
Standigm Korea South

The workflow AI drug discovery company

Growth
23 employees
AI, Biotechnology
Accutar Biotech vs
Ainnocence
Ainnocence United States

AI For Better Medicine

Seed
12 employees
AI, Biotechnology

FAQ About Accutar Biotech

Employ AI to Revolutionize Drug Discovery
Accutar Biotech was founded in 2015.
Accutar Biotech is headquartered in Brooklyn, United States.
Accutar Biotech operates in AI, Biopharma, Biotechnology and Machine Learning. Its work centres on AI Drug Discovery, Computation-aided Drug Design, Flexible Mode Ligand Docking and Virtual Screening. Its customers include Pharmaceutical Companies, Biotech Firms and Healthcare Researchers.
Accutar Biotech has a B2B, SaaS and API business model. Its revenue comes from Licensing, Service Fee and Subscription.
Accutar Biotech has approximately 38 employees.
Accutar Biotech has completed 6 funding rounds, raising a total of $72.75M.
Accutar Biotech offers: AI Solutions for Drug Discovery, Drug Design and Development, AI-Powered Biological System Analysis, Data-Driven Chemical Analysis.
Top alternatives and competitors to Accutar Biotech include Genesis Molecular AI, Standigm, Ainnocence, Ascent Bio, Ro5. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Accutar Biotech and Genesis Molecular AI are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Accutar Biotech, https://bouncewatch.com/company/accutar-biotech, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout